Brief: Klaria Signs Exclusive Development, License And Supply Agreements With Purdue Pharma
Jan 22 (Reuters) - Klaria Pharma Holding AB (publ) KLAR.ST :
* KLARIA SIGNS EXCLUSIVE DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTS WITH PURDUE PHARMA
(CANADA)
FOR THE EMERGENCY TREATMENT OF ANAPHYLACTIC REACTIONS
* IN ADDITION, KLARIA WILL RECEIVE MID-TO-UPPER SINGLE DIGIT ROYALTIES ON NET SALES
Source text for Eikon: ID:nWkr7mMtkl
Further company coverage: KLAR.ST
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Klaria Pharma Holding AB (publ)
See all newsBrief: Klaria Gets Additional Subscription Commitments, Extends Subscription Period
Brief: Klaria Pharma Publishes Summary Of External Valuation
Brief: Klaria Pharma To Decide On Rights Issue Of Up To SEK 147.6 Mln
Brief: Klaria Pharma To Carry Out Rights Offering
Brief: Klaria, RTHS Enter Collaboration Agreement